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Little is known about the difference in gene expression between carcinoma-associated fi-
broblasts (CAFs) and paired normal colonic fibroblasts (NCFs) in colorectal cancer. Paired
CAFs and NCFs were isolated from eight primary human colorectal carcinoma specimens.
In culture conditions, soluble factors secreted by CAFs in the conditioned media increased
clonogenicity and migration of epithelial cancer cells lines to a greater extent than did NCF.
In vivo, CAFs were more competent as tumour growth enhancers than paired NCFs when
co-inoculated with colorectal cell lines. Gene expression analysis of microarrays of CAF
and paired NCF populations enabled us to identify 108 deregulated genes (38 upregulated
and 70 downregulated genes). Most of those genes are fibroblast-specific. This has been
validated in silico in dataset GSE39396 and by qPCR in selected genes. GSEA analysis re-
vealed a differential transcriptomic profile of CAFs, mainly involving the Wnt signallingsig-
nalling pathway, focal adhesion and cell cycle. Both deregulated genes and biological
processes involved depicted a considerable degree of overlap with deregulated genes re-
ported in breast, lung, oesophagus and prostate CAFs. These observations suggest that
similar transcriptomic programs may be active in the transition from normal fibroblast
in adjacent tissues to CAFs, independently of their anatomic demarcation. Additionally
NCF already depicted an activated pattern associated with inflammation.
The deregulated genes signature score seemed to correlate with CAF tumour promoter abil-
ities in vitro, suggesting a high degree of heterogeneity between CAFs, and it has also prog-
nostic value in two independent datasets.d gene; CAF, carcinoma-associated fibroblast; NCF, normal colonic fibroblasts; ECM, extra-
; fax: þ34 93 2607466.
.net, davidg.mollevi@gmail.com (D.G. Mollevı).
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provide cancer cells with a suitable microenvironment andmay help in the development of
new therapeutic targets for cancer treatment.
ª 2014 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.1. Introduction attack tumour-supportive CAFs and could add valuable infor-The tumour microenvironment is a place where tumour cells
co-exist and co-evolve with “non-tumoral” cells such as adi-
pocytes, fibroblasts, endothelial and immune cells, all of
which are embedded in an extracellular matrix (ECM). When
changes occur in this compartment, the altered stroma can in-
fluence cancer development and progression (Bissell et al.,
1982; Bissell and Hines, 2011). Carcinoma-associated fibro-
blasts (CAFs), the main constituents of tumour stroma,
actively drive tumourigenesis and cancer progression
(Elenbaas and Weinberg, 2001; Hwang et al., 2008; Olumi
et al., 1999; Orimo et al., 2005; Zhang et al., 2009). They partic-
ipate throughout tumour development by establishing
cellecell interactions with tumour cells or through secretion
of cytokines, chemokines and growth factors. CAFs are most
often denoted by the expression of a-smooth muscle actin
(aSMA), but other markers such as vimentin and fibroblast-
activating protein (FAPa) are also used to identify them.
Nevertheless, these are alsomarkers ofmyofibroblasts or acti-
vated fibroblasts, and not properly and exclusively of CAFs. An
exclusive marker for CAFs that can clearly distinguish them
from normal fibroblasts from adjacent mucosa or other
closely related cell types is yet to be identified. Chang et al.
(2002) reported that transcriptional patterns displayed by fi-
broblasts from different anatomic sites were distinct and
characteristic, and suggested that fibroblasts from different
organs could be considered as distinct differentiated cell
types. However, in a subsequent study, the same group
defined a common transcriptomic profile in fibroblasts stimu-
lated with serum and with a pattern similar to that observed
in a wound healing process and associated with tumour pro-
gression (Chang et al., 2004). It is known that the involvement
of CAFs in solid tumours, in which desmoplasia is a character-
istic feature, is of huge importance. Gene expression profiles
and their association with cancer aggressiveness, has been re-
ported in several tumours types (Peng et al., 2013). The current
work is focused on colorectal cancer, in which, to our knowl-
edge, the genetic and molecular profile of CAFs has been less
thoroughly explored. The purpose of this study is to identify,
for the first time in paired samples, genes that are differen-
tially expressed in two fibroblast populations derived from
the same colorectal cancer (CRC) patients (NCFs and their
paired CAFs from primary tumour) and to examine their asso-
ciations with phenotypic differences. Using microarray tech-
nology, we identified 109 deregulated probes (corresponding
to 108 genes) differentially expressed between the two popula-
tions and functionally involved in cancer progression. Knowl-
edge of alterations in the stroma surrounding a tumour might
provide tools and biomarkers of use in designing new ways tomation for future and prognostic treatments.2. Materials and methods
2.1. Culture of primary fibroblasts and preparation of
conditioned medium
Fresh surgical specimens from colorectal cancer patientswere
obtained with the approval of the Ethics Committee of the
Hospital Universitari de Bellvitge (IDIBELL). Tissue samples
from morphologically normal colonic mucosa (at least 5 cm
from the surgical margin), and from colorectal primary
tumour wereminced and incubated with collagenase and dis-
pase for 2 h at 37 C. Cells were resuspended and plated with
Dulbecco’s modified Eagle’s medium-F12 (DMEM F12, Gibco)
containing 10% fetal bovine serum (FBS) and penicillin/strep-
tomycin antibiotics. Primary fibroblast cultures were estab-
lished and routinely maintained at 37 C in a humidified
atmosphere containing 5% CO2. After a maximum of 5 pas-
sages, RNA and protein were obtained to check for fibroblast
purity. 106 fibroblasts were incubated for 48 h in 10-cm diam-
eter dishes in DMEM-F12 with or without FBS. Conditioned
medium was collected, centrifuged for 5 min at 3000 rpm to
remove cell debris, sterile-filtered through 0.22-mm filter units
(Millex GS, Millipore) and stored at 80 C until use.
2.2. In vitro cellular assays
Migration of cancer cells and CAFs was measured by wound
healing assay. Cells were seeded in 6-cm diameter plates
and cultured until confluent. The cell monolayer was
scratched with a yellow 200-ml pipette tip to create a wound.
After several PBS (phosphate-buffered saline 1) washes to
remove floating cells, in an epithelial cell migration assay,
conditioned medium from NCF or CAF was added. Pictures
were taken at different times. Distances between cell margins
were measured with Leica software (Wetzal, Germany) on
three occasions and each assay was performed in duplicate.
Clonogenic capacity was assessed by cloning assay.We plated
100 cells for each epithelial colon cancer cell line (DLD1,
SW620, SW480 and SW1116) in 12-well plates and incubated
them for 9 days in DMEM F12 10% (control) or the appropriate
conditionedmedium. The number of colonies was counted af-
ter crystal violet staining. AWST-1 cell proliferation assaywas
conducted in CAFs alone and in DLD1 cells stimulated with
CAF conditioned medium (CM) (24 h without FBS being
collected, as mentioned above). Briefly, 1000 cells were seeded
in a 96-well plate and cultured at several times (0, 24, 72 and
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attached. After performing the time assay, the culture me-
dium was removed and replaced with 10 ml of WST-1 reagent
(Cell Proliferation Reagent WST-1, Roche) in 100 ml serum-free
DMEM/F12. Absorbance at 450 nm was measured after 2 h in-
cubation (37 C, 5% CO2, in darkness).
2.3. Western blot analysis
To extract total protein, monocultured fibroblasts were ho-
mogenized with RIPA lysis buffer (PBS 1, 1% SDS, 1%
nonidet-40, 0.5% sodium deoxycholate), supplemented with
complete EDTA-free Protease Inhibitor Cocktail Tablets
(Roche), orthovanadate, PMSF, b-glycerol and leupeptin. Ly-
sates were cleared by centrifugation and protein samples
were loaded onto SDS/polyacrylamide gels and transferred to
polyvinylidenefluoridemembranes.Membraneswere blocked
for 1hat roomtemperature in10%nonfatmilkand0.1%Tween
in TBS 1, washed, and incubated overnight at 4 C with the
corresponding dilution of primary antibodies. A second incu-
bation was performed using ECL horseradish peroxidase-
linked secondary murine/rabbit antibody (GE Healthcare),
and enhanced chemiluminescence was detected by Novex
ECL chemiluminescent substrate reagent kit (Invitrogen).
2.4. Antibodies and reagents
Epithelial colon cancer cell lines DLD1, SW620, SW480, SW1116,
HCT116, HCT-15, CaCO2, LoVo, Colo205, RKO, KM12C, HT-29,
Co115were purchased from the American Type Culture Collec-
tion (ATCC).All cell linesweremaintainedinDMEM-F1210%FBS
with added antibiotics. Primary antibodies used inwestern blot
were: pre-diluted anti-a smooth muscle actin (Abcam) at 1/3
dilution, anti-vimentin (Invitrogen) at 1/1000, anti-vinculin
(Invitrogen)at 1/400,anti-E-cadherinandN-cadherin (BDBiosci-
ences) at 1/500, VE-cadherin (Abcam) and Tubulin (Sigma) at 1/
3000 and 1/500 dilutions respectively.
2.5. In vivo tumorogenicity assay
Hsd: Athymic Nude-Foxn1nu mice were co-injected subcutane-
ously in the right and left lateral flanks, with 1.2  106 DLD1
colon cancer cells alone (n ¼ 4 injections) or in combination
with 5  105 NCF (n ¼ 5 different NCFs, n ¼ 10 coinjections)
or CAF (n ¼ 5 different CAFs, n ¼ 10 coinjections). Each exper-
iment was repeated twice. Only two pairs NCF/CAF from the
same patient were tested. After only 21 days, the volume of
the generated tumours using CAFs was >2 cm3 in some cases
and the affected mice had to be sacrificed. Tumour volume
and weight were determined. Additionally, we evaluated
Ki67 to assess the proliferative status of tumour cells (Dako
antibody clone MIB-1) and human specific Vimentin immuno-
histochemical staining (Dako antibody clone V9), for
evidencing the presence of the coinjected human fibroblasts.
2.6. RNA isolation and quantitative real-time PCR (qRT-
PCR)
Total RNA from different isolated fibroblasts and colorectal
cancer cell lines was extracted using TRIzol reagent methodand column purification using PureLink RNA Mini Kit (Invi-
trogen). RNA quantity was determined by NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies Inc., Rock-
land, DE) and 100 ng of total RNA was reverse-transcribed us-
ing M-MLV reverse transcriptase (Invitrogen) following the
manufacturer’s instructions. A 0.1-mg equivalent of the corre-
sponding cDNAwas used for each quantitative PCR assay per-
formedwith the LightCycler 480, SYBR Green I Master (Roche
Applied Science, Mannheim, Germany). Primers were
designed using Primer3 Input (http://primer3.wi.mit.edu)
and predicted PCR product sequences were verified using
BLAST (http://www.ncbi.nlm.nih.gov/blast). All primer se-
quences can be provided upon request.2.7. Microarray analysis
RNA from 8 paired NCF/CAF cultures was extracted as
described above. TotalmRNAwas hybridized in an Affymetrix
GeneChip Human Gene 1.0 ST Array. All computations and
statistical analyses were performed using the R language
and environment (R Development Core Team, 2008). The
microarray data were read, normalized, and transformed to
numerical expression values using the justRMA function in
the simpleaffy package (Wilson and Miller, 2005). The resulting
data were used to look for genes that were differentially
expressed between groups (NCF vs. CAF) using the Significance
Analysis of Microarrays (SAM) technique, available in the samr
package (Tusher et al., 2001). To obtain a reduced list of genes,
we considered those with a false discovery rate (FDR) < 0.05
and a >2-fold change.2.8. Gene set enrichment analysis and gene ontology
Gene set enrichment analysis (GSEA) (Subramanian et al.,
2005) was applied to the pre-ranked list of differentially
expressed genes (by value of SAM d statistic). We wanted to
determine whether there was enrichment (ES) in our deregu-
lated genes list for particular pathways described in previ-
ously known gene sets. This bioinformatics tool analyzes the
complete list of deregulated genes and allows small but coor-
dinated changes in expression to be taken into consideration.
The statistical significance of the ES was estimated from 1000
gene permutations. We used gene sets C2.CP.KEGG.v4.0 and
C2.CP.ALL.v4.0.
Functional gene ontology (GO) annotation of genes of inter-
est (FDR q-value < 0.1) was performed using the DAVID data-
base. Gene functional classification and functional
annotation clustering were performed to identify functional
gene groups and ontology terms that were significantly over-
represented among the genes of interest.2.9. Cocultures of NCF with colorectal cancer cell lines
The same NCF isolated to obtain transcriptomic profiles
were used to establish five days transwell cocultures with
colorectal cancer cell lines (DLD1 cells). Total mRNA
was hybridized in an Affymetrix GeneChip Human Gene
1.0 ST Array. All procedures were performed as described
in 2.7.
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The signature score for each of the fibroblasts included in the
array was obtained by computing the standardized values of
all 109 probes (108 genes) comprising the signature. Score
values were plotted for each NCF/CAF pair.
The relevance of the signature score in an in vitromodelwas
assessed by evaluating phenotypic differences in terms of pro-
liferation in the two isolated fibroblasts with the greatest dif-
ference in score (according to microarray expression data).
High and low score CAFs were selected for various functional
assays for the purpose of elucidating phenotypic differences.
2.11. Validation of proinflammatory genes in GSE44076
A set of 98 paired adjacent-normal and tumour tissues from
CRC patients and 50 colon mucosa from healthy donors (246
samples in total) were included in this dataset. Patients were
selected to form a homogeneous clinical group of stage II, mi-
crosatellite stable (MSS) colorectal tumours. All had been
treated with radical surgery, had not received adjuvant ther-
apy and had a minimum follow up of three years. Adjacent
normal tissue from patients was dissected from the resection
margins, with aminimum distance of 10 cm from the tumour.
Healthy donors were invited to participate in this study when
they received a colonoscopy indicated for screening or symp-
toms, but with a result of no lesions in the colon. All samples
were selected from Bellvitge University Hospital-IDIBELL
(Spain) and the protocol was approved by the Ethics Commit-
tee. Written and informed consent from patients and healthy
donors was required for inclusion in this study. RNA extracted
from each sample was hybridized in Affymetrix chips Human
Genome U219. After a quality control assessment following
Affymetrix standards, data was normalized using the RMA al-
gorithm. Both raw and normalized data are available in the
Gene Expression Omnibus (GEO) database with accession
number GSE44076.
Additionally, we used 10 healthy colonic mucosas, 10
normal adjacent mucosas and 10 paired tumours to validate
by means of quantitative RT-PCR some of the differentially
expressed genes between NCF and CAFs.
2.12. Prognostic analysis
Available annotated clinical data for GSE17537 (Smith et al.,
2010) and GSE14333 (Jorissen et al., 2009) datasets included
AJCC staging, age, gender and disease-free survival intervals.
We analysed time to recurrence in stage IeIII patients using
the pooled GSE17537-GSE14333 dataset. To remove systematic
biases between datasets, expression levels for all genes were
transformed to z-scores before pooling. We reinforced the
prognostic value in an independent dataset of stage II patients
(GSE33113) (de Sousa et al., 2011). These datasets were chosen
since no epithelial cell enrichment was performed on the
sample (whole tumour samples).
To assess the predictive power of the gene signatures on
recurrence we computed the mean signature expression of
overexpressed genes and tested its significance with a univar-
iate Cox proportional hazards model likelihood ratio test. The
mean signature expression was computed from z-scoresobtained for each of the genes and from summation z-scores
across all genes in the signature.
We derived KaplaneMeier survival curves for patients,
dividing the cohort into two risk groups, using the mean as
the cut-off (zero). We obtained a smooth estimate of the rela-
tionship between mean signature expression and recurrence
hazard ratio (smoothCoxph function in the phenoTest pack-
age). Low and high signature expression (low and high risk,
respectively) were defined as values below and above the
mean, respectively. We also segregated the cohort into three
risk groups (low, medium and high risk) with respect to the
smooth estimate of the recurrence hazard ratio vs. the gene
signature score. Statistical significance of the average signa-
ture score, introduced as a continuous covariate in the Cox
model, was determined. Statistically significant variables
from the univariate model were included in a multivariate
Cox model, which also included age, gender, AJCC stage and
study/hospital of data collection as adjustment covariates.
Statistical significance was concluded for values of p < 0.05.
Survival analyses were done in the Biostatistics and Bioin-
formatics Unit of the Institute for Research in Biomedicine,
Barcelona, Spain.
Finally we validate by means of quantitative RT-PCR some
of the differentially expressed genes betweenNCF and CAFs in
60 samples of stage II/III colorectal cancer patients from our
institution (30 non-recurrent and 30 recurrent).3. Theory
Given the relevance that the tumour stroma is taking from the
data provided by recent molecular classifications, the DEG be-
tween normal colonic fibroblasts obtained from adjacent mu-
cosa and carcinoma-associated fibroblasts might be a tool to
develop a gene classifier with a limited number of genes in or-
der to predict outcome in colorectal cancer patients. The iden-
tification of a signature with prognostic value is a filter to
remove those genes least likely to provide useful information
to categorize patients according to their risk of recurrence.
Our group is currently working to develop a 5-gene classifier
basedonamoreamenable techniquesuchasquantitative PCR.4. Results
4.1. Isolation and characterization of CAFs and NCF
Cultures of carcinoma-associated fibroblasts (CAFs) and their
paired normal colonic fibroblasts (NCFs) from adjacent colon
mucosa from 8 patients were successfully established. Addi-
tionally, 5 NCFs and 5 CAFs (unpaired samples) were also iso-
lated. The fibroblast cell population was first verified by cell
morphologyunder themicroscope. Figure1Ashows the typical
spindle-like shape of theNCFs andCAFs. The purity of isolated
fibroblasts was checked by detection of specific fibroblast bio-
markers. These cells strongly expressed vimentin, vinculin,
and a-smoothmuscle actin (aSMA), whereas theyweremostly
negative for cytokeratin 18, E-cadherin (epithelial markers),
and VE-cadherin (endothelial marker). These expression
changes were checked by qRT-PCR or western blot in the 8
Figure 1 e Characterization of fibroblasts isolated from human colon cancer tissue. A) Cultured CAFs and their normal NCF counterparts
visualized under the microscope, showing their characteristic cell morphology. B) Relative expression of specific mesenchymal markers such as
vimentin and a-SMA in the 8 paired NCF/CAF cell lines (samples included in the array analysis) and in four more pairs NCF/CAF. None of them
showed a specific pattern between the two types of fibroblasts, indicating that although they were good mesenchymal biomarkers, they did not
discard between NCFs and CAFs. Low levels of the epithelial-specific marker cytokeratin 18 confirmed the purity of the fibroblast cultures. C)
Protein levels of additional specific fibroblastic markers were tested by western blot, confirming the purity of the fibroblast cultures (samples are
ordered in pairs). D) Immunohistochemical staining of a-SMA in a specimen from a colorectal cancer patient, illustrating staining of
myofibroblasts in both compartments, normal adjacent mucosa and adenocarcinoma. All the fibroblasts surrounding the non-tumoral crypts are
positive for a-SMA.
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(Figure 1B and C). The results indicated that fibroblast cells
were correctly isolated from tumour tissue and adjacent mu-
cosa. Astonishingly, levels of aSMA in NCF were in some cases
comparable to those in CAFs. To exclude any interference
because of in vitro culturing we checked aSMA staining in
tumour specimens. As displayed in Figure 1D, normal adjacent
mucosa also stained for aSMA, confirming that some fibro-
blasts in adjacent normal mucosa are also myofibroblasts an
observation also recently noticed by Hawinkels et al. (2014).
4.2. CAFs enhance aggressiveness of colorectal cancer
cell lines in vitro
In a wound-healing assay, CAF CM increased the migratory
potential of DLD1 cancer cells compared with NCF CM
(Figure 2A). We also observed that when different colorectal
cancer cell lines (DLD1, SW620, SW480 and SW1116) were
exposed to CM from CAFs, their clonogenic capability wasenhanced after 9 days of culture (Figure 2B). We previously
described the differential proliferative capacity of CMs
depending on the fibroblast origin in different colorectal cell
lines (Berdiel-Acer et al., 2011).
4.3. In vivo tumorogenic assay
In an in vivo assay, when DLD1 cells were co-injected in com-
bination with NCF, there were no differences weight
compared with the DLD1 cells injected alone (P ¼ 0.460, U
ManneWhitney test). However, co-injection of DLD1 with
CAFs significantly accelerated tumour growth (Figure 2C).
Additionally we observed an intense Ki67 staining in tumours
generated with the coinjection of DLD1 cells þ CAF while the
staining was very mild when coinjection were made with
NCF (Figure 2D). Interestingly, after 21 days we still observed
the presence of CAFs but not of NCFs through human-
specific vimentin staining, demonstrating the replicative ca-
pabilities of CAFs in a xenogeneic environment (Figure 2D).
Figure 2 e Functional assays of CAFs vs. NCFs. A) In a wound-healing assay, DLD1 cells significantly increased their migratory potential when
cultured with CAF conditioned medium (CM), compared with their normal paired CM (left and right panels). B) The clonogenic capacity of four
cell lines (DLD1, SW620, SW480 and SW116) was greater in the presence of 6 CMs from CAFs compared with 6 CMs from NCFs (two replicates
per CM). C) Co-injection of CAFs with DLD1 cancer cells into athymic mice significantly enhanced tumour growth compared with NCFs
(P < 0.0001). D) Hematoxylin-eosin and immunohistochemical staining. 21 days after coinjection, human specific vimentin were detected in
almost all slides of tumours generated with DLD1 cells D CAFs. No staining was detected in tumours DLD1 cells D NCF. In addition, DLD1
cells in tumours generated with CAFs displayed high levels of Ki67 staining at the periphery of the tumours, whereas the staining was very mild in
case of coinjection with NCF.
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paired NCFs
To explain the biological heterogeneity betweenCAFs andNCFs
in the primary colorectal cancer microenvironment, the gene
expression profile of CAFs and their normal counterparts from
8 colorectal cancer patients was obtained using the Affymetrix
GeneChip Human Gene 1.0 ST Array. Microarray data were
normalized with RMA and differentially expressed genes
(DEG) were identified using Significance Analysis in Microarrays
(SAM). The gene list obtained was ranked according to the
FDR q-value <0.05 and a >2-fold change (in genes overex-
pressed inCAFs) and a<0.5-fold change (genes underexpressed
in CAFs). We identified 109 probes that were differentially
expressed in CAFs vs.NCFs, 39 upregulated probes correspond-
ing to 38 known genes, and 70 downregulated probes corre-
sponding to 70 known genes. The ranked list of the 108 genes
deregulated between NCF and CAF is summarized in
Supplementary Table 1. Expression profiles of statistically sig-
nificant genes overexpressed in CAFs and NCFs were explored
by unsupervised sample-based cluster analysis. Hierarchical
clustering clearly separates CAFs and NCFs and allowed us to
classify matched samples depending on whether they came
from tumour or from adjacentmucosa (Figure 3A). We checked
the expression of some selected genes (CDH2, ENC1, TNFSF4,
ST6GALNAC5, SEMA5A, SLC7A2 and TGFB2) by western blot,
and confirmed that in the paired fibroblasts tested, overexpres-
sion was also translated at protein level to almost all pairs
(Figure 3B). Quantitative RT-PCR validation of some of these
differentially expressed genes in samples of colonic mucosa
from healthy patients (n ¼ 10), adjacent colonic mucosas
(n ¼ 10) and paired colorectal tumours (n ¼ 10) confirmed the
expression values obtained in cultured fibroblasts (Figure 3C).
4.5. Normal colonic fibroblasts adjacent to the tumour
expressed pro-inflammatory genes
Surprisingly, many proinflammatory cytokines, FGFR ligands
and other secreted proteins of the TNF family were overex-
pressed in NCF compared to counterpart CAFs. This fact was
validated comparingmRNA levels in 50healthy colonicmucosa
and 98 paired normal adjacent mucosa and colorectal carci-
noma (GSE44076). As shown in Supplementary Figure 1A, the
expression was confirmed, demonstrating that normal adja-
cent mucosa has already proinflammatory changes compared
to normal healthy mucosa (PROS1, FGF13, CCL8, CXCL12,
FGF13, SLIT3, FGF7, FGF10, SFRP1) suggesting certain degree of
activation of fibroblasts from the adjacent mucosa. Such acti-
vated status was also confirmed for classical fibroblast activa-
tion markers like endosialin (CD248), aSMA (ACTA2) and
vimentin (VIM) in samples from healthy mucosas, adjacent
mucosas and paired tumours (Supplementary Figure 1B). Other
cytokines like CCL11, CCL13 or TNFSF10 are higher in both
healthy mucosa and adjacent mucosa compared to tumour.
4.6. Fibroblast specificity of the differentially expressed
genes
Additionally, the CAF-specificity of the 108 deregulated genes
was checked in GSE39396, a dataset corresponding to sixdifferent colorectal cancer patients and the expression profile
of four sorter-isolated cell types (endothelial cells: CD31þ,
epithelial cells: EPCAMþ, inflammatory cells: CD45þ and
CAFs: FAPaþ) (Calon et al., 2012). According to GSE39396
data, many of the genes could be considered to be solely
expressed in fibroblast cells (those framed in green in
Figure 4A and B; i.e: TGFB2, AMIGO2, PDLIM3, ENC1 or RARB).
A small proportion of genes are basically expressed at a higher
level in epithelial cells (framed in red). Other genes are more
characteristic of endothelial cells, and finally, there is a group
of genes that are expressed ubiquitously in various stromal
cells.
To validate themicroarray data, the expression levels were
analysed by qRT-PCR in isolated fibroblasts (8 pairs included in
the array and 5more pairs), and in a set of 13 colorectal cancer
cells (CRCs). Validated genes were chosen according to their
gene product, considering some of those coding for mem-
brane proteins and soluble factors such as TNFSF4, SEMA5A,
ST6GALNAC5, CLDN1, EFNB2, PKP2 (Rickelt et al., 2009), NTF3
(Louie et al., 2013), TGFB2, ULBP2 and CXCL12 (Figure 4C). Addi-
tionally we validated some genes with a >2-fold change and a
q-value between 0.05 and 0.10, like WNT2, NRXN3, INHBA,
FGF13 and COL11A1 (Figure 4D). The expression pattern of
the genes differentially expressed between NCFs and CAFs
detected by qRT-PCR was consistent with the microarray re-
sults and the absence or low level of expression of most of
the selected genes in a set of 13 epithelial colon cancer cell
lines confirmed their stromal specificity.
4.7. Functional annotation and GSEA
To evaluate the biological significance of coordinated varia-
tion in expression changes observed between NCF and CAF
transcriptomic programs, we performed GSEA for the com-
plete list of ranked genes. We determined that the expression
profile of overexpressed genes in CAFs correlated with fibro-
blast serum response genes, whereas underexpressed genes
were associatedwith serum or core serum response repressed
genes (Supplementary Figure 2). These results were consistent
with those of Chang et al. (2004), who suggested that in pros-
tate and hepatocellular carcinoma, normal tissue samples had
the serum-repressed signature, while tumours had the
serum-induced signature or “wound-healing phenotype”.
GSEA also revealed that genes deregulated in CAFs were
related to different KEGG pathways, the most representative
overexpressed pathways with FDR <0.01 are depicted in
Table 1. DAVID (Database Annotation, Visualization and Inte-
grated Discovery) was used to classify the gene function of
deregulated genes in CAFs and their paired NCFs applying a
q-value of <0.1 as a cut-off (305 underexpressed probes,
p ¼ 0.003; 97 overexpressed probes, p ¼ 0.001). Gene ontology
analysis (Supplementary Table 2) revealed that genes overex-
pressed in CAF were associated with biological processes
related to development (TGFB2, PDGFC, cMET, CADM1, WNT2)
and cellecell signalling (TFAP2C, NTF-3, SEMA5A, EFNB2, and
INHBA). On the other hand, underexpressed genes were clus-
tered in categories involved in homeostasis (SNCA, AGT,
ABCA1, PLA2G4A, and BCL-2), response to external stimulus
(CCL8, CCL7, CCL11, CCL13, proS1) and cellecell signalling
(FGF10, FGF13, TNFSF10, NOVA1).
Figure 3 e Unsupervised heatmap of deregulated genes in CAF vs. NCF. A) Genes differentially expressed in 8 paired CAFs vs. NCFs. A total of
108 differentially expressed genes, 70 downregulated (yellow side bar) and 38 upregulated (green side bar), were identified by SAM analysis.
Fibroblasts were clustered independently of their patient origin. B) Expression of some upregulated genes in CAFs was tested and confirmed at the
protein level by western blot, except for the pair highlighted with the red dashed line in the densitometry analysis (CDH2, SLC7A2 and TGFB2).
C) Quantitative RT-PCR validation of 11 of the differentially expressed genes in 10 healthy colonic mucosas (blue bars), 10 adjacent normal
mucosas (red bars) and 10 paired tumours (green bars). Expression values are expressed as z-scores obtained from the relative expression values
normalised for two housekeeping genes (PMM1 and ACTB).
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Transcriptomic profile of NCFs change after 5 days coculture in
transwell inserts with tumour cells (DLD1 cells), acquiring
expression values for many of the differentially expressedgenes similar to those observed in paired CAFs
(Supplementary Figure 3). The paracrine interaction between
both cell types induces gene expression changes in NCF even
for inflammatory cytokines like CCL11, CCL8 or the apoptotic
inducer TNFSF10 (Supplementary Figure 3B, low panel).
Figure 4 e CAF specificity of deregulated genes. A-B) Unsupervised heatmaps of deregulated genes (overexpressed and underexpressed,
respectively) in the GSE39396 dataset. The expression profile of 108 deregulated genes was checked in 4 CRC cell populations: FAPaD
(fibroblasts), EPCAMD (epithelial cells), CD45D (leukocytes) and CD31D (endothelial cells). Gene expression levels clearly classified cells into
the correct class. Of the complete list of genes, almost half are specific to the fibroblast cell type population (green box). A set of stromal genes
heterogeneously expressed in all cell types but not in epithelia are depicted in black as a mixed group of stromal genes. A group of genes is mostly
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Signature scores for the isolated fibroblasts used in the array
were obtained by adding up the expression values for all 108
deregulated genes. The score confirmed that the expression
of those selected genes allowed the two fibroblast populations
to be discriminated (Figure 5A) and emphasized the relevance
of genetic disparity between the two types of fibroblasts even
though they had the same origin (same patient). To identify
any phenotypic differences associated with score values, we
chose the CAFs that differed most in expression (high and
low scores) and evaluated differences in migration and prolif-
eration. In a wound-healing assay, when we assessed the
migratory capacity of fibroblasts, we found higher scores
were associated with more migration (Figure 5B). Concerning
proliferation ability, after a 144 h MTT assay, high-score
CAFs showed greater proliferation compared with their low-
score counterparts (ManneWhitney test, p ¼ 0.05; Figure 5C).
When epithelial tumour cells (DLD1) were cultured with CAF
CM (mentioned above), an increase in cell proliferation was
evident if cultured with high score signature CM compared
with the one from low-score signature CAFs (ManneWhitney
test, p ¼ 0.034; Figure 5D).
4.10. Prognostic value of the signature score
Wewanted to assess the association of the score of the differ-
entially expressed genes with prognosis in colorectal cancer.
Using two different independent datasets, the pooled cohort
GSE14333-17537 (Stages I-to-III) and GSE33113 (Stage II), using
the mean value, zero, as a cut-off, patients with a low signa-
ture score displayed a significantly different disease-free sur-
vival time than high-scoring patients (Cox regression,
p ¼ 0.0038 for pooled cohort GSE14333-GSE17537, p ¼ 0.026
for GSE33113; Figure 5E upper left panel and lower panel).
Treating the signature score as a continuous variable, the haz-
ard ratio was HR¼ 1.48 (95% CI 1.13e1.94, p¼ 0.004 per unit in-
crease in the pooled cohort GSE14333-GSE17537 and HR ¼ 1.89
(95% CI 1.14e3.12, p ¼ 0.011) in GSE33113.
We validated the expression of some of the differentially
expressed genes by means of quantitative RT-PCR in 30 sam-
ples from non-recurrent stage II/III tumours and 30 samples
from recurrent stage II/III tumours. As illustrated in
Figure 5G, genes that we found overexpressed in CAFs vs
NCFs were higher in recurrent tumours and genes overex-
pressed in NCFs vs CAFs were higher in non-recurrent
tumours.5. Discussion
Using microarray technologies, this study identifies for the
first time transcriptomic differences between carcinoma-expressed in endothelial cells (blue box) but not in the other cell types. C) E
PCR in paired (n [ 12), as well as in a set of 13 colorectal cancer cells lin
specificity in the vast majority of selected genes. D) We expanded PCR vali
false discovery rate q-value < 0.1.associated fibroblasts (CAFs) and their paired normal colonic
fibroblasts (NCFs) in patients with primary colorectal carci-
nomas.We defined a 108-gene signature that better character-
ises each fibroblast subpopulation and is also correlated with
the proliferative and migratory properties of the CAFs. Thus,
the higher the score signature, the more competent the fibro-
blasts are in terms of proliferation and migration.
We have previously reported differential effects at the
functional level of CM from unpaired fibroblasts from loca-
tions where a colorectal cancer is situated (i.e., normal mu-
cosa, primary tumour or a liver metastasis) (Berdiel-Acer
et al., 2011). Other authors compare transcriptomic profiles
of CAFs vs normal fibroblasts from healthy tissues (Torres
et al., 2013). In the present work, to go further and relate tran-
scriptomic differences with the phenotype, we ascertained
that CAFs clearly enhanced the aggressiveness of colorectal
cancer cells with respect to their NCF counterparts. We
demonstrated that CM obtained from CAFs confers a higher
migratory and clonogenic capacity than in paired NCF and is
dependent on their signature score. We also confirmed that
CAFs are more proficient in vivo as tumour promoters than
NCFs from the same patient, although being both cell types
myofibroblasts.
Differences between the two cell subpopulations have also
been described in terms of gene expression profiles in several
solid tumours (Bauer et al., 2010; Costea et al., 2013; Hawsawi
et al., 2008; Navab et al., 2011; Peng et al., 2013); but, as far as
we are aware, not for colorectal cancer using paired samples.
In addition, all these aforementioned published works are
focused on the assumption that CAFs present in malignant
tissues are derived from normal resident fibroblasts on
healthy tissues (Bauer et al., 2010; Costea et al., 2013;
Hawsawi et al., 2008; Navab et al., 2011; Peng et al., 2013). Other
authors suggested that different cells could be precursors of
myofibroblasts, like bone marrow mesenchymal stem cells
(MSCs) (Quante et al., 2011; Guo et al., 2008) or from epithelial
normal or transformed cells via epithelial to mesenchymal
transition (EMT), or finally from endothelial cells via endothe-
lial to mesenchymal transition (EndMT) (Cirri and Chiarugi,
2012). Although we cannot exclude any of the previous hy-
pothesis and evenmany of themmight be happening simulta-
neously (Worthley et al., 2010), in our opinion the activation
and recruitment of normal resident pericryptal fibroblasts is
the most plausible theory, since the coculturing of NCF with
tumour cells induces transcriptional changes in fibroblasts
acquiring a transcriptomic profile more similar to their paired
CAFs (Supplementary Figure 3).
We have assessed the gene expression profile of CAFs
and their normal paired counterparts in colon cancer sam-
ples in order to identify: (i) relevant pathways responsible
for pro-tumorogenic effects; (ii) new biomarkers for cancer
treatment focused on the stroma and (iii) we evaluate the
prognostic value of differentially expressed genes. Using 8xpression levels of selected deregulated genes was validated by qRT-
es. Results confirmed the microarray data and demonstrated stromal
dation to some genes with a >2-fold change in expression but with a
Table 1 e GSEA analysis (Kegg pathways) of genes deregulated in CAFs.
Name Size ES NES NOM p-val FDR q-val
GSEA KEGG pathways overexpressed in CAFs
HSA04510_FOCAL_ADHESION 189 0.235 3441 0 0.00Eþ00
HSA04110_CELL_CYCLE 111 0.290 3297 0 0.00Eþ00
HSA04310_WNT_SIGNALING_PATHWAY 146 0.219 2878 0 0.00Eþ00
HSA04810_REGULATION_OF_ACTIN_CYTOSKELETON 197 0.186 2766 0 6.28E04
HSA05222_SMALL_CELL_LUNG_CANCER 85 0.274 2756 0 5.02E04
HSA05213_ENDOMETRIAL_CANCER 52 0.337 2754 0 4.19E04
HSA04360_AXON_GUIDANCE 126 0.207 2590 0 9.67E04
HSA05215_PROSTATE_CANCER 86 0.244 2528 0 1.11E03
HSA05223_NON_SMALL_CELL_LUNG_CANCER 53 0.308 2523 0 9.88E04
HSA05214_GLIOMA 63 0.287 2518 0 8.89E04
HSA04520_ADHERENS_JUNCTION 75 0.248 2429 0 1.81E03
HSA04514_CELL_ADHESION_MOLECULES 129 0.202 2420 0 1.75E03
HSA05220_CHRONIC_MYELOID_LEUKEMIA 76 0.250 2405 0 1.78E03
HSA04670_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION 107 0.209 2346 2.08E03 2.38E03
HSA05211_RENAL_CELL_CARCINOMA 68 0.250 2299 2.10E03 3.36E03
HSA04115_P53_SIGNALING_PATHWAY 65 0.248 2249 4.12E03 4.43E03
HSA04512_ECM_RECEPTOR_INTERACTION 86 0.217 2214 0.00Eþ00 5.32E03
HSA04530_TIGHT_JUNCTION 129 0.175 2180 2.11E03 6.61E03
HSA05212_PANCREATIC_CANCER 73 0.229 2177 2.07E03 6.33E03
HSA00562_INOSITOL_PHOSPHATE_METABOLISM 47 0.275 2168 2.20E03 6.18E03
HSA05210_COLORECTAL_CANCER 84 0.212 2164 2.11E03 6.08E03
HSA05130_PATHOGENIC_ESCHERICHIA_COLI_INFECTION_EHEC 50 0.266 2163 2.11E03 5.80E03
HSA01430_CELL_COMMUNICATION 135 0.172 2150 2.06E03 5.99E03
HSA05131_PATHOGENIC_ESCHERICHIA_COLI_INFECTION_EPEC 50 0.266 2140 2.02E03 6.05E03
HSA03050_PROTEASOME 22 0.388 2113 4.17E03 7.16E03
HSA04012_ERBB_SIGNALING_PATHWAY 83 0.207 2101 2.24E03 7.70E03
HSA05221_ACUTE_MYELOID_LEUKEMIA 53 0.255 2098 4.36E03 7.50E03
HSA04070_PHOSPHATIDYLINOSITOL_SIGNALING_SYSTEM 73 0.218 2041 8.44E03 1.13E02
HSA04540_GAP_JUNCTION 93 0.186 1981 8.32E03 1.57E02
HSA04120_UBIQUITIN_MEDIATED_PROTEOLYSIS 39 0.273 1944 4.19E03 1.91E02
HSA00190_OXIDATIVE_PHOSPHORYLATION 125 0.159 1940 6.52E03 1.90E02
HSA00970_AMINOACYL_TRNA_BIOSYNTHESIS 37 0.283 1929 1.43E02 1.98E02
HSA04210_APOPTOSIS 81 0.191 1919 2.11E03 2.01E02
HSA04916_MELANOGENESIS 99 0.176 1903 2.03E03 2.19E02
HSA00240_PYRIMIDINE_METABOLISM 85 0.183 1897 8.46E03 2.18E02
HSA04320_DORSO_VENTRAL_AXIS_FORMATION 27 0.311 1860 1.58E02 2.58E02
HSA05218_MELANOMA 71 0.185 1754 1.30E02 4.45E02
GSEA KEGG pathways infraexpressed in CAFs
HSA00980_METABOLISM_OF_XENOBIOTICS_BY_
CYTOCHROME_P450
61 0.438 3.869 0.00Eþ00 0.00Eþ00
HSA00641_3_CHLOROACRYLIC_ACID_DEGRADATION 15 0.728 3.249 0.00Eþ00 0.00Eþ00
HSA00350_TYROSINE_METABOLISM 58 0.382 3.213 0.00Eþ00 0.00Eþ00
HSA00071_FATTY_ACID_METABOLISM 45 0.423 3.201 0.00Eþ00 0.00Eþ00
HSA00561_GLYCEROLIPID_METABOLISM 57 0.364 3.100 0.00Eþ00 0.00Eþ00
HSA00480_GLUTATHIONE_METABOLISM 35 0.456 2.993 0.00Eþ00 0.00Eþ00
HSA00120_BILE_ACID_BIOSYNTHESIS 38 0.423 2.931 0.00Eþ00 1.32E04
HSA03320_PPAR_SIGNALING_PATHWAY 65 0.306 2.764 0.00Eþ00 3.39E04
HSA00624_1_AND_2_METHYLNAPHTHALENE_DEGRADATION 23 0.496 2.748 0.00Eþ00 3.02E04
HSA00010_GLYCOLYSIS_AND_GLUCONEOGENESIS 63 0.298 2.601 0.00Eþ00 4.44E04
HSA00590_ARACHIDONIC_ACID_METABOLISM 50 0.324 2.581 0.00Eþ00 4.04E04
HSA04060_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 245 0.149 2.324 0.00Eþ00 3.41E03
HSA00380_TRYPTOPHAN_METABOLISM 58 0.272 2.278 0.00Eþ00 4.76E03
HSA00220_UREA_CYCLE_AND_METABOLISM_OF_AMINO_GROUPS 30 0.343 2.181 1.89E03 7.75E03
HSA00280_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION 44 0.283 2.167 5.66E03 7.91E03
HSA00512_O_GLYCAN_BIOSYNTHESIS 29 0.339 2.156 0.00Eþ00 8.27E03
HSA03010_RIBOSOME 62 0.241 2.107 4.04E-03 9.76E03
HSA04610_COMPLEMENT_AND_COAGULATION_CASCADES 68 0.222 2.060 1.97E03 1.34E02
HSA00340_HISTIDINE_METABOLISM 41 0.271 1.946 2.01E03 2.68E02
HSA00410_BETA_ALANINE_METABOLISM 25 0.336 1.897 5.92E03 3.46E02
HSA00640_PROPANOATE_METABOLISM 34 0.289 1.875 7.81E03 3.73E02
HSA02010_ABC_TRANSPORTERS_GENERAL 44 0.249 1.830 1.17E02 4.63E02
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Figure 5 e Signature score. A) NCFs and CAFs used in the microarray were plotted according to their signature score (expression level of all 108
deregulated genes). Expression levels of those genes clearly separated the two fibroblast populations even though they came from the same patient.
Fibroblasts used in subsequent functional assays are highlighted with a blue “L” (low score), and a red “H” (high score). B) Migration rates of CAFs
were proportional to signature scores, the high score CAFs being the fastest to close the wound. C) CAFs with higher 108-signature scores had a
higher proliferation rate than those with lower expression levels. D) When conditioned media from the same fibroblasts were added to a colorectal
cancer cell line (DLD1), significant differences were observed between CM from a high score CAF vs CM from low score CAF (ManneWhitney
test, p [ 0.034). E) Prognostic value of the differentially expressed genes in a pooled cohort (GSE14333-GSE17537) of stages I-to-III colorectal
patients. Left and middle panels show KaplaneMeier plots for disease-free survival, by the two risk groups (left panel; using the mean value as a
cut off) or stratifying into three risk groups, using a smooth function of risk of recurrence based on the signature score (middle panel). The smooth
function correlates the gene signature score with the relative risk of recurrence. Red dashed lines: 95% confidence interval (CI). Grey dashed lines:
thresholds for patient selection into groups depicted in the middle panel: low (L; blue, 40 patients), medium (M; gray, 187 patients), and high (H;
red, 40 patients); p values and increases in HR per standard deviation increase in expression (D1 SD) are shown (right panel). F) The prognostic
value was corroborated using 90 colorectal patients stage II (GSE33113). G) Quantitative RT-PCR validation of some differentially expressed
genes (four upregulated and four downregulated in CAFs vs NCFs) in 30 non-recurrent stage II/III colorectal tumours and 30 recurrent stage II/
III colorectal tumours maintaining stages proportionality between the two groups.
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genes that were differentially expressed between the two
fibroblast populations. Unsupervised hierarchical cluster
analysis of the expression data from the 108 genes clearly
differentiated two patterns on the basis of the fibroblasts’
anatomic location. Furthermore, the knowledge of genetic
changes that occur when normal colonic fibroblasts from
adjacent tissues are transformed into CAFs could help us
elucidate pathways involved in the education of fibroblasts
by tumour cells and to understand how to overcome such
crosstalk between the cell types. Such information may
provide relevant biomarkers for future treatments (target
discovery) or tumour classification. Regarding canonical
pathways responsible for pro-tumorogenic effects of
CAFs, it is remarkable that GSEA correlates overexpressed
genes in CAFs with a higher proliferative status (cell cycle)
and signatures associated with fibroblasts response to
serum (Chang et al., 2004) (wound healing phenotype). By
contrast, integrating GSEA and DAVID (http://david.abcc.n-
cifcrf.gov) overexpressed genes in NCF from adjacent mu-
cosa clustered into categories involved in homeostasis
and metabolism. This fact might explain the dual role of
the microenvironment as a tumour suppressor, while ho-
meostasis is maintained, or as a tumour promoter when
the homeostatic balance is lost (Bissell and Hines, 2011).
Initially astonishing, we observed higher levels of several
proinflammatory cytokines, TNF family molecules and FGFR
ligands in NCF. These values were validated using 50 colonic
mucosa samples of healthy volunteers, 98 adjacent normal
mucosa and their paired colorectal carcinomas, confirming
higher levels of CCL11, CCL8, CCL13, FGF10 or TNFSF10, among
others, in normal adjacent mucosa compared to colorectal
carcinomas. Even classical genes associated with an activated
status of fibroblasts (ACTA2, VIM, CD248) were higher in
normal adjacent mucosas compared with normal mucosas
fromhealthy patients (Supplementary Figure 1B). Such valida-
tion confirms that adjacentmucosa already has changes, con-
firming also the values of aSMA detected in cultured NCF. In
addition, someone might speculate why adjacent tissue re-
sponds with such activated state. One possibility might be a
consequence of paracrine crosstalk with the tumour to create
an adequate niche for the tumour to increase their size and
invade. Another possibility could be a defensive response of
the host. But further experiments are needed to solve this
observation.
These results differ significantly compared to recent pub-
lications (Torres et al., 2013). In this manuscript, authors
compare CAFs from mice with normal fibroblasts obtained
from healthy mice. Additionally, chemically induced colitis-
associated colorectal models in mice did not recapitulates
the desmoplastic reaction and lack the invasive and metasta-
tic phenotypes of human tumours (De Robertis et al., 2011).
Moreover, stromal factors responsible for tumour promotion
in colitis-associated colorectal cancer differ from the stromal
factors, mainly fibroblasts, which promote sporadic colo-
rectal cancer in humans. Thus, in order to find relevant mol-
ecules for target discovery, it would be more adequate to use
specific CAF markers not expressed by their counterpart resi-
dent fibroblasts in adjacent tissues. Otherwise, undesired
side effects may affect normal fibroblasts in adjacent tissue.In relation to this, some of the DEG in CAFs could be inter-
esting druggable targets for treating cancer (especially those
secreted or membrane receptors), in order to selectively
remove those fibroblasts which exerted a protective action
against the damage induced by chemotherapy on malignant
cells (http://dgidb.genome.wustl.edu/). Retinoic acid receptor
b (RARB) is consistently overexpressed in CAFs versus coun-
terpart NCF from adjacent mucosa. Stromal RARb has already
been shown to promote mammary gland tumorogenesis, in
large part, mediated through the CXCL12/CXCR4/ErbB2 sig-
nalling pathway. Ablation of RARB leads to a remodelling of
the stroma during tumour progression that includes a
decrease in angiogenesis, in the recruitment of inflammatory
cells, and in the number myofibroblasts (Liu et al., 2011). The
availability of different retinoids (i.e: Tamibarotene) could be
interesting approaches for the treatment of cancer, especially
to hamper the crosstalk between stroma and tumour cells.
Another interesting gene differentially expressed in CAFs
versus counterpart NCF to be targeted is TGFB2. At present
there are therapies targeting specifically this growth factor
(belagenpumatucel-L), currently in phase III in non-small
cell lung cancer (Nemunaitis et al., 2009; Decoster et al., 2012).
Interestingly, there was a remarkable overlap considering
our 108 deregulated genes from data previously obtained
from breast (Bauer et al., 2010), lung (Navab et al., 2011) and
oesophageal carcinoma (Zhang et al., 2009), whereby TNFSF4,
ST6GALNAC5, TGFB2, TFAP2C and LEF1 are among the most
overexpressed genes, and NOVA1, PDE3B, SLIT3, AKR1C1,
AKR1C2 are among the most underexpressed. The degree of
overlap is highly remarkable when relaxing the stringent cri-
terion of SAM false-discovery rate q-value of <0.1. A funda-
mental consideration of the biological pathways involved in
such transcriptional programs compared with previous data
from breast, lung and oesophagus, (focal adhesion, Wnt
signaling pathway, axon guidance, among others), leads us
to consider the stimulated common processes in these site-
specific CAFs. In other words, the crosstalk between tumour
cells and fibroblasts in the microenvironment might depend
on similar events and signalling pathways, with the conse-
quences that this may have for finding good druggable targets
to disrupt the communication between the two cell types.
These observations suggest that, roughly, similar transcrip-
tomic programsmight be active in the transition from normal
adjacent fibroblast to CAFs independently of the anatomic
demarcation, and strongly support the existing correlation be-
tween cancer and the “wound-healing phenotype”.
Another aspect is the degree of activation of such pro-
cesses, since fibroblasts are highly heterogeneous cells as
reported by Herrera et al. (2013). Other authors have sug-
gested that such heterogeneity might be related to their
possibly miscellaneous origin (Worthley et al., 2010).
Regarding this heterogeneity, we have also demonstrated
that the score of the 108-gene signature is correlated
with functional parameters of CAFs, such as their migra-
tory or proliferative capacity, and that this may link the
signature with a desmoplastic reaction. We propose that
fibroblasts with higher scores are those that are recruited
in large quantities in highly desmoplastic colorectal tu-
mours. Some authors have reported that the more fibro-
blasts there are in a tumour, the worse is the prognosis
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we found an association with disease-free survival in
two independent datasets of whole-tumour samples,
whereby the higher the level of expression of those DEG,
the worse the prognosis. Interestingly those genes have a
prognostic value when considering Stage II patients
(GSE33113). Since controversy exists when treating stage
II patients with chemotherapy, CAFs might provide rele-
vant information to take clinical decisions. Additionally,
the performance of the signature in independent, whole
tumour-derived data sets indicates that although the prog-
nostic ability of those genes is basically specific of tumour
stroma, the signal can be detected in and the signature
can predict outcome in datasets from whole tissue. Addi-
tionally, we confirmed that the prognostic ability of our
signature score was not simply a reflection of tumours
with high fibroblast content by computing the quantity
of fibroblasts from the expression values of COL1A1 and
COL3A1 (as surrogate markers) in a cohort of 142 cases
of whole-tumour colorectal specimens, and showing that
high collagen tumours have the same risk of recurrence
as low collagen tumours (data not shown). It should be
noted that DEG have predictive value for patient outcome
in non-advanced and advanced-stage tumours, indicating
that the heterotypic interactions between stroma and
epithelium are already relevant at the initial steps of the
tumorogenic process. CAFs prognostic information could
be then useful to select patients even at earlier stages
that may benefit from treatment (i.e. Stage II risk tumours,
T4N0).
Another important aspect might involve the fibroblast
specificity of a given gene, especially considering possible bio-
markers for target discovery. For some deregulated genes,
expression was checked by means of quantitative RT-PCR in
13 CRC cell lines and also in four isolated populations (CAFs,
epithelial cells, endothelial cells and CD45þ cells) obtained
from six colorectal cancer patients. Approximately the 50%
of deregulated probes belong to genes specifically expressed
in fibroblasts and only 15% were genes mainly expressed by
epithelial cells. Another group of genes could be considered
to be stromal genes since they are also expressed in endothe-
lial and inflammatory cells and even a group of ubiquitously
expressed genes.
In order to find a reliable CAF gene classifier for prognostic
purposes, the present work, using matched cases sharing the
same genetic background, constitutes a filter to discard genes
with less variation with counterpart NCF and genes ubiqui-
tously expressed.6. Conclusions
This study contributes evidence of the role of CAFs in the
biology and progression of colorectal carcinoma and identifies
an association between these phenotypic features and
changes in gene expression compared with paired NCFs. We
also identify new biomarkers that could differentiate normal
adjacent fibroblasts from tumour fibroblasts and that could
be useful for finding strategies to break the shell that protects
tumour cells in desmoplastic tumours. Additionally, thesubset of deregulated genes provides an opportunity to
develop a gene classifier for categorising patients according
to their level of risk.Funding
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